Presenting at CMSC 2021, researchers sought to identify which of the 8 tasks on the Memory for Intensions Test has the best classification accuracy, sensitivity, and specificity for detecting prospective memory issues in patients with multiple sclerosis.
Researchers investigated the 5-year safety and efficacy of dimethyl fumarate under routine care in patients with multiple sclerosis in the ESTEEM trial.
Presenting at CMSC 2021, researchers evaluated the efficacy and safety of arbaclofen extended-release tablets in patients with multiple sclerosis-related spasticity.
Researchers surveyed caregivers for people diagnosed with multiple sclerosis and/or Alzheimer disease about key stressors, access to caregiving resources, and their interactions with health care providers.
Presenting at CMSC 2021, researchers investigated the casual relationships between measures of obesity and the genetic risk for multiple sclerosis.
Presenting at CMSC 2021, researchers examined the relationship between synesthesia and multiple sclerosis.
Researchers sought to verify and analyze the relationship between symptoms of depression and attention performance in patients with multiple sclerosis.
Researchers assessed the efficacy and safety of repository corticotropin injection in patients with relapsing-remitting multiple sclerosis relapse with an inadequate response to high-dose corticosteroids.
Using an in vitro model of decreased heterogeneous nuclear ribonucleoprotein A1 (A1), researchers sought to determine the impact of A1 nuclear function loss on neuronal health and viability.
Researchers assessed whether the frequency and severity of COVID-19 differed by disease-modifying therapies among patients with multiple sclerosis (MS) who received care in the NYU MS Care Center.
